Table 3 Ongoing clinical trials evaluating the safety and efficacy of immune checkpoint inhibitors in patients with SCLC

NCT03043872

3

ES-SCLC

PD-L1 inhibitor + Chemo

Durvalumab + Chemo vs. Chemo

268 vs. 269

–

13.0 vs. 10.3 months

5.1 vs. 5.4 months

62% vs. 62%

NCT03728361

2

Metastatic NEN

PD-1 inhibitor + chemo

Nivolumab + temozolomide

11(Lung) vs. 17(Others)

64% vs. 18%

NR vs. 32.3 months

11.1 vs. 7.2 months

43% (of all)

NCT02402920

1

ES-SCLC

Chemo + TRT + PD-1 inhibitor

Chemo + TRT + Pembrolizumab

38

–

8.4 months

6.1 months

0%

NCT04624204

1/2

LS-SCLC

CRT + PD-1 inhibitor

CRT + Pembrolizumab

40

–

39.5 months

19.7 months

45/40